The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Changing the Paradigm: Omegaven for the Treatment of Liver Failure in Pediatric Short Bowel Syndrome
Abstract
Background: Parenteral omega‐3 fatty acids, such as Omegaven, may benefit patients with pediatric short bowel syndrome (SBS) who develop parenteral nutrition–associated liver disease (PNALD). Patients and Methods: Retrospective cohort describing the outcome of all 12 children with SBS and advanced PNALD who were treated with Omegaven (target omega‐6 to omega‐3 fatty acid ratio = 1:1 to 2:1). Results: The median age was 7.5 (range 3.6–46) months, and median parenteral nutrition duration before starting Omegaven was 28.4 (range 15.3–55.3) weeks. Median initial serum conjugated bilirubin was 137 (range 54–203) μmol/L (8.06 [3.18–11.94] mg/dL). Of the 12 patients, 9 had complete and sustained resolution of hyperbilirubinemia within a median of 24 (range 7–37) weeks, and all are no longer being considered for liver transplantation. Improvements in markers of hepatic inflammation as well as nutritional status also were noted in these patients. Three patients received a liver‐intestine transplant while taking Omegaven. There were no complications attributable to Omegaven. Conclusions: Omegaven is associated with restoration of liver function in patients with SBS and advanced liver disease. Parenteral omega‐3 fatty acids, such as Omegaven, have the potential to fundamentally alter the paradigm of neonatal SBS from one of early death or transplantation from liver failure to a more chronic disease. More children with SBS should achieve full enteral tolerance and those who do not have the capacity for intestinal adaptation should be able to survive and receive an intestinal graft when older.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162
Cited by
Intestinal Transplant Registry Report: Global Activity and Trends
Grant, D., Abu-Elmagd, K., Mazariegos, G., Vianna, R., Langnas, A., Mangus, R., Farmer, D. G., Lacaille, F., Iyer, K., & Fishbein, T. (2015) · American Journal of Transplantation · doi:10.1111/ajt.12979 · Cited by 449
Parenteral Fish Oil Improves Outcomes in Patients With Parenteral Nutrition-Associated Liver Injury
Puder, M., Valim, C., Meisel, J. A., Le, H. D., de Meijer, V. E., Robinson, E. M., Zhou, J., Duggan, C., & Gura, K. M. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181b36657 · Cited by 385
ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Lipids
Lapillonne, A., Fidler Mis, N., Goulet, O., van den Akker, C. H. P., Wu, J., Koletzko, B., Braegger, C., Bronsky, J., Cai, W., Campoy, C., et al. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2018.06.946 · Cited by 277
Lipids in the intensive care unit: Recommendations from the ESPEN Expert Group
Calder, P. C., Adolph, M., Deutz, N. E., Grau, T., Innes, J. K., Klek, S., Lev, S., Mayer, K., Michael-Titus, A. T., Pradelli, L., et al. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.08.032 · Cited by 158
Chen, B., Zhou, Y., Yang, P., Wan, H., & Wu, X. (2010) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607110362532 · Cited by 112
Metadata
- Authors
- Diamond, I. R., Sterescu, A., Pencharz, P. B., Kim, J. H., & Wales, P. W.
- Venue
- Journal of Pediatric Gastroenterology and Nutrition
- Publisher
- Wiley
- Published
- 2009-02
- Volume
- 48
- Issue
- 2
- Pages
- 209-215
- ISSN
- 0277-2116 (ISSN-L)
- 1536-4801
- OpenAlex
- W2070369077
- Cited by
- 251
- References
- 1
- FWCI
- 21.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Changing the Paradigm: Omegaven for the Treatment of Liver Failure in Pediatric Short Bowel Syndrome. https://app.cochat.ai/papers/10.1097/mpg.0b013e318182c8f6
- The paper
- Diamond, I. R., Sterescu, A., Pencharz, P. B., Kim, J. H., & Wales, P. W. (2009). Changing the Paradigm: Omegaven for the Treatment of Liver Failure in Pediatric Short Bowel Syndrome. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1097/mpg.0b013e318182c8f6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.